May 13, 2022 8:00am EDT Ocuphire Pharma Announces Financial Results for First Quarter 2022 and Provides Corporate Update
May 11, 2022 8:00am EDT Ocuphire Pharma Announces Upcoming Presentations at the Retina World Congress, Clinical Trials at the Summit, and the H.C. Wainwright Global Investment Conference
Apr 28, 2022 7:00am EDT Ocuphire Completes Last Clinical Trial Supporting the Planned 2022 NDA Submission with the Announcement of Positive Results from MIRA-4 Pediatric Safety Trial Evaluating Nyxol® for Reversal of Mydriasis